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Abstract
Insulin-secreting beta cells within the Islets of Langerhans decrease in mass 
during the pathophysiology of diabetes. The ability to track beta cell loss in vivo 
by a non-invasive imaging tool would effectively identify pre-diabetes and follow 
islet transplant fate. The glucagon-like peptide-1 (GLP-1) receptor is expressed 
in the membrane of beta cells and serves as a suitable biomarker for beta cell 
targeting. This thesis outlines the characterization of a library of GLP-1 
analogues modified to resist enzymatic degradation and carry an imaging 
isotope. Binding affinity, cAMP activation and plasma stability were determined to 
identify a candidate probe for in vitro and in vivo imaging of beta cells. 
Biodistribution assays revealed specific uptake of a 68Ga-GLP-1 analogue in the 
pancreas of C57BL/6 mice; however, beta cells were not observed in SPECT or 
PET images. Attempts made to reduce kidney accumulation demonstrated the 
need for further modifications to facilitate beta cell imaging.
Keywords
Beta cell imaging, diabetes mellitus, nuclear imaging, single photon emission 
computed tomography (SPECT), positron emission tomography (PET), glucagon­
like peptide-1, GLP-1, glucagon-like peptide-1 receptor, GLP-1 R.
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The face of molecular imaging is constantly evolving with new technologies and 
tools emerging to help better understand disease processes and biological 
information. Improvements in technology allow us to explore, non-invasively, 
molecular targets with higher sensitivity, better spatial resolution, the ability to 
quantify them and a desire to understand and cure disease. Molecular imaging is 
unique in its multidisciplinary nature, requiring the expertise of radiochemists, 
biochemists, molecular biologists, physicists, engineers, imaging technologists, 
and physicians. This thesis presents novel and challenging, yet exciting, results 
of a molecular imaging project that contributes to diabetes research.
Chapter 1 focuses on the discussion of diabetes mellitus and a rationale for 
developing a tool that can target beta cells and track changes in beta cell 
mass/volume during the disease process and/or during regenerative therapy.
Chapter 2 presents the results I obtained while characterizing novel GLP-1 
analogues and using them to imaging the beta cells in vivo.
Chapter 3 will conclude with a discussion of the significance of the obtained 
results and recommendations for future endeavours.
1.1 Diabetes Mellitus
Diabetes is a serious, chronic disease that affects the endocrine pancreas. There 
are two major types of diabetes: type 1 and type 2, collectively known as
2
diabetes. Type 1, also known as ‘juvenile-onset diabetes’, is characterized by a 
near-complete loss in the insulin-producing beta cells in the Islets of Langerhans 
(islets) of the pancreas caused by autoimmune destruction. In a healthy 
pancreas, these islets are dispersed unevenly among the head, neck and tail 
regions of the pancreas and also accommodate other hormone-secreting cells 
(Tornehave, Kristensen, Romer, Knudsen, & Heller, 2008). Together, the 
hormone-producing cells make-up the endocrine component of the islet which 
accounts for about 1% of the total pancreatic weight and less than 0.005% of the 
adult body weight; these cells include: glucagon-secreting alpha cells, insulin- 
secreting beta cells, somatostatin-secreting delta cells, pancreatic polypeptide 
(PP)-secreting cells, and ghrelin-secreting epsilon cells (Cabrera et al., 2006; 
Prado, Pugh-Bernard, Elghazi, Sosa-Pineda, & Sussel, 2004). Interestingly, islet 
architecture differs between species; in mice and rat islets, the beta cells are 
clustered within a core surrounded by alpha cells, while in humans, beta cells are 
dispersed evenly amongst the other endocrine cells types (Cabrera et al., 2006).
Type 1 diabetes is directly caused by T-cell-mediated autoimmune destruction of 
the beta cells, leading to the complete loss of insulin secretory capacity (Palmer 
et al., 2004). It has been hypothesized that the presence of certain antibodies 
can trigger beta cell autoimmunity (Taplin & Barker, 2008). The presence of 
persistent positive antibodies to the islet cell (ICA), insulin (IAA), glutamic acid 
decarboxylase (GAA) or protein tyrosine phosphatase (IA2) is said to be highly 
predictive of developing type 1 diabetes. Furthermore, the presence of multiple
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aforementioned antibodies collectively increases type 1 diabetes susceptibility 
(Verge et al., 1996).
In contrast to type 1, there are several direct causes that lead to the onset of type 
2 diabetes. The main characteristic of type 2 diabetes is insulin resistance in 
peripheral target tissues, such as the liver and muscle, caused by the altered 
post-receptor signaling pathway subsequent to the binding of insulin to its 
receptor. Genetic, pathologic, environmental and metabolic abnormalities can 
increase the chance of developing type 2 diabetes, although it is largely 
preventable. A sedentary lifestyle including poor diet and exercise increases 
one’s chance of developing type 2 diabetes. Diabetes begins with metabolic 
abnormalities including increased hepatic glucose output and insulin resistance 
in several tissues (Souza et al., 2006). Initially, the beta cells will attempt to 
compensate for the increased circulating glucose by increasing insulin output in a 
stage referred to as ‘hyperinsulinemia’. Eventually, the beta cells cannot 
compensate further and begin the process of apoptosis, leading to diminished 
insulin secretory capacity and hyperglycemia.
1.1.1 Diabetes in Canada
In Canada, more than three million people live with diabetes, the majority of 
whom have type 2. The World Health Organization has declared diabetes a 
‘global epidemic’ with an estimated 285 million people worldwide - 6.6% of the 
world’s population - living with diabetes as of 2009 (International Diabetes 
Federation, 2009). An estimated 3.7 million Canadians will have diabetes by
4
2020 at which time the economic burden will be approximately $16.9 billion per 
year (Canadian Diabetes Association, 2009).
Complications caused by diabetes include heart disease and stroke -  
cumulatively causing 80% of diabetic deaths -  as well as nephropathy, 
retinopathy, and neuropathy (Canadian Diabetes Association, 2009). Several 
lifestyle modifications can be implemented to delay or prevent type 2 onset, as 
discussed above; however, methods to prevent type 1 are still largely unknown.
Although no direct ‘cure’ for diabetes currently exists, several treatments for type 
1 and 2 diabetes are being developed. Type 2 diabetics are advised to make 
positive lifestyle changes in combination with pharmacologic treatments aimed to 
reduce insulin resistance, inhibit glucagon secretion, and stimulate insulin 
secretion (Souza et al., 2006). Type 1 diabetics typically rely on exogenous 
insulin therapy which, by no means, cures diabetes; however, several 
experimental treatments aimed to reduce insulin-dependence have been 
developed, including islet transplantation.
1.1.2 Islet Transplantation as a Potential Therapy for Type 1 
Diabetes
The Edmonton protocol of islet transplantation dramatically improved transplant 
therapy outcome in patients with severe type 1 diabetes (Shapiro et al., 2000). 
Since then, a multi-centre study investigating islet transplant therapy success 
after 1 year has reported that insulin independence increased from 8% to 31% 
(Shapiro et al., 2006). The reports of the three-year follow-up concluded that
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although only 17% of transplant recipients were insulin-independent after three 
years, islet transplant therapy is still a viable option for individuals seeking 
glycemic control (Shapiro et al., 2006). Furthermore, inclusion criteria for islet 
transplant candidates remain stringent -  mainly because of the low source of 
potential islet donors -  and, as a result, around 0.1% of type 1 diabetics receive 
transplants each year (Rother & Harlan, 2004). Islets are commonly transplanted 
into the liver via transfusion into the portal vein and patients are required to take 
immunosuppressants to avoid allograft rejection. In the liver, the beta cells must 
revascularize and sustain glucose-dependent insulin secretion. Subsequent post­
transplant glycemic control is assessed using techniques that predominantly 
measure beta cell function such as fasting glucose levels and C-peptide 
measurements (Shapiro et al., 2000). No tool that can directly measure beta cell 
mass clinically currently exists but would, without a doubt, provide a more 
accurate account of islet viability post-transplantation. Measuring beta cell 
function as a predictor of beta cell mass is not ideal since significant loss in beta 
cell mass occurs before deficiencies in beta cell function can be detected.
1.2 Focusing-in on the Beta Cell
1.2.1 Tracking Changes in Beta Cell Mass in vivo
From the perspective of the clinician, a non-invasive tool to measure the 
progression of beta cell loss and regeneration in patients with diabetes who have 
undergone transplantation would be extremely beneficial to determine prognosis 
and treatment strategies. Current measures of assessing beta cell function are 
both accurate and sensitive, but cannot provide an accurate index of beta cell
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mass; it has been shown that beta cell loss precedes dysfunctional insulin 
secretory capacity years before the onset of diabetes (Sreenan et al., 1999; Van 
Belle, Coppieters, & Von Herrath, 2011). Directly measuring insulin as a marker 
of beta cell function is impractical since insulin is rapidly metabolized in the liver, 
and insulin assays cannot differentiate between exogenous and endogenous 
insulin (Palmer et al., 2004). The most sensitive and widely used measurement 
of beta cell function is the measurement of endogenous C-peptide levels (Palmer 
et al., 2004). C-peptide, along with insulin, is derived from proinsulin and 
secreted from the beta cells in the presence of glucose. C-peptide is co-secreted 
with insulin in equal molar ratios but, unlike insulin, is not immediately processed 
by the liver. Instead, C-peptide’s half life of 30 min allows sufficient time for 
evaluation. C-peptide measurement has been selected as the most suitable 
primary outcome measurement for experimental therapies aimed at restoring 
endogenous insulin secretory capacity in type 1 diabetics (Palmer et al., 2004). A 
more suitable primary outcome measurement would be the direct measurement 
of beta cell mass. Detecting the preliminary signs of diabetes can allow the 
clinician to determine the time to start preventive measures to delay the 
predisposition or the onset of the disease. A tool that can accurately measure 
beta cell mass would facilitate detection of prediabetes and, additionally, the 
success of islet transplantation therapy.
1.2.2 Beta Cell Targeting
In light of the above issues, the development of an injectable probe that can 
accurately and non-invasively report beta cell mass is undisputedly warranted.
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Several research groups have aimed to identify biomarkers specific to the beta 
cell in hopes of developing a tool that can be used for accurate beta cell mass 
(Moore, 2009; Souza et al., 2006; Wu & Kandeel, 2010). Three prominent 
biomarkers include: the beta cell-specific IC2 antibody which binds to a sulfatide 
epitope galactose-3-sulphate present in the insulin granula (Saudek, Brogren, & 
Manohar, 2008); vesicular monoamine transporter-2 (VMAT2) which is 
hypothesized to be expressed solely in the beta cell; and glucose transporter 2 
(GLUT2) which is specific to the beta cells, renal tubular cells and hepatocytes. It 
is crucial that the biomarker be specific only to the beta cell and not the 
neighboring endocrine cells (i.e. alpha, delta cells or PP cells) or the exocrine 
pancreas (i.e. ductal or acinar cells). Ideally, the biomarker will be consistently 
expressed between beta cells and bind with high affinity to its probe. One 
suitable biomarker is the GLP-1 receptor (GLP-1R).
1.2.3 The GLP-1 Receptor as an Attractive Target for Beta Cell 
Mass Estimation
Glucagon-like peptide-1 (GLP-1) stimulates glucose-dependent insulin secretion 
subsequent to binding to its receptor, the GLP-1 receptor (GLP-1 R), and will be 
discussed in more detail in the next section. The GLP-1 R is located within the 
cell membrane of the pancreatic beta cell. It is a member of family B of the G- 
protein-coupled receptors superfamily; these receptors require a ligand to bind to 
their extracellular N-terminus which results in activation of a signaling pathway 
from the intracellular C-terminus. When the GLP-1 receptor is activated by the 
binding of its natural ligand, GLP-1, it causes formation of 3'-5'-cyclic adenosine
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monophosphate (cAMP) and stimulates insulin exocytosis. The bound GLP-1R is 
then endocytosed, or internalized, by the beta cell into endosomes where the 
GLP-1 will eventually dissociate from the GLP-1 R which is recycled back to the 
plasma membrane (Widmann, Dolci, & Thorens, 1995). The GLP-1 R is 
structurally identical in both humans and mice and has been shown to be 
expressed in the heart, kidneys, stomach, lung, brain and predominantly in the 
beta cells of the pancreas (Tornehave et al., 2008; Wei & Mojsov, 1995). One 
study has reported GLP-1 R mRNA expression in somatostatin and glucagon 
positive cells (Heller, Kieffer, & Habener; 1997); however, recent studies have 
not been able to substantiate these findings using fluorescence microscopy 
(Tornehave et al., 2008). Despite its rather widespread distribution, the GLP-1 R 
is an attractive biomarker for beta cell imaging and mass estimation because it is 
specific to the beta cells in the pancreas (Tornehave et al., 2008). Furthermore, 
GLP-1 R density is relatively higher in the beta cells (1,322 ± 143 dpm/mg tissue) 
compared to other GLP-1 R-expressing tissues such as the kidney (674 ±12 7  
dpm/mg tissue), ileum (887 ± 285 dmp/mg tissue), and colon (788 ± 84 dpm/mg 
tissue) (Korner, Stockli, Waser, & Reubi, 2007). Finally, GLP-1 R agonists and 
antagonists have been identified and can be modified to target and bind the GLP- 
1R with high affinity.
1.3 The Glucagon-Like Peptide-1
1.3.1 The Functions of Proglucagon-derived Peptides in vivo
The GLP-1 is a potent insulin-secreting peptide derived from its precursor, 
proglucagon. Proglucagon is expressed from the preproglucagon gene and
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serves as a precursor for several peptides including glucagon, GLP-1 and GLP-
2. Proglucagon is synthesized in the alpha cells of the pancreas, intestinal L- 
cells, and in the brainstem neurons, and is post-translationally processed to 
different peptides in these tissues (Campos, Lee, & Drucker, 1994). Proglucagon 
is post-translationally processed to glucagon in the alpha cells by the 
prohormone convertase 2 (PC2) (Furuta et al., 2001). It was originally 
hypothesized that glucagon was the only bioactive proglucagon-derived peptide 
synthesized in the alpha cells; however, it has been shown that trace amounts of 
GLP-1 are synthesized in the alpha cells in response to hyperglycemia (Nie et 
al., 2000). Glucagon is released from the alpha cells of the endocrine pancreas in 
response to hypoglycemia, and is the major counter-regulatory hormone to 
insulin; the balance of these two hormones maintains euglycemia.
Glucagon-like peptide-2 (GLP-2) is also a peptide derived from proglucagon and 
is a product of the post-translational processing of proglucagon by prohormone 
convertase 1 (PC1) (Dhanvantari, Seidah, & Brubaker, 1996). GLP-2 is secreted 
along with GLP-1 in the intestinal L-cells in a nutrient-dependent manner. GLP-2 
exerts its major action on the intestines where it stimulates small bowel epithelial 
proliferation (Drucker, Erlich, Asa, & Brubaker, 1996).
GLP-1 is synthesized into two equipotent forms: GLP-1 (7-37) and GLP-1 (7-36) 
amide -  collectively referred to as GLP-1 -  in response to nutrient ingestion. 
Although much of GLP-1 is produced in the distal regions of the intestine, it is 
released into the circulation within minutes of food ingestion in response to
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neural and hormonal signals in the proximal gut (Drucker & Nauck, 2006). Once 
GLP-1 is liberated by the post-translational modification of proglucagon by PC1 
in the intestine, it acts upon the pancreas and several extra-pancreatic organs 
including the brain, heart, stomach, liver, and muscles (Baggio & Drucker, 2007; 
Dhanvantari et al., 1996). Primary functions of GLP-1 in the pancreas include 
glucose-dependent insulin secretion, and serve as a beta cell cytoprotective 
agent by increasing beta cell proliferation and decreasing beta cell apoptosis (Li, 
El-Kholy, Rhodes, & Brubaker, 2005). GLP-1’s effects in the brain include control 
of satiety (Turton et al., 1996) and body weight (Meeran et al., 1999) and a 
cardioprotective function following cardiac injury in rat hearts (Bose, Mocanu, 
Carr, Brand, & Yellon, 2005).
1.3.2 GLP-1 as a Potential Imaging Probe
GLP-1 has the potential to serve as an imaging probe for two reasons. First, 
structure-function relationships of ligand-receptor binding have been extensively 
characterized for GLP-1 R (Adelhorst, Hedegaard, Knudsen, & Kirk, 1994; 
Knudsen, 2004). These studies have cited the importance of the N-terminus of 
GLP-1 for high-affinity receptor binding to the GLP-1 R and the C-terminus for 
receptor recognition (Adelhorst et al., 1994). Specifically, 7Histidine, 10Glycine, 
12Phenylalanine, 13Threonine, and 15Aspartic acid are essential for receptor 
binding and should not be modified (see Figure 1A for abbreviations and 
positions) (Adelhorst et al., 1994). Amino acids involved in GLP-1 R recognition 
include 28Phenylalanine and 29lsoleucine (Adelhorst et al., 1994). Any 
remaining amino acids may not directly interact with the receptor (Adelhorst et
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al., 1994) and are therefore available for modification to carry an imaging agent 
or to improve resistance to enzymatic degradation (Figure 1). Second, GLP-1 
specifically binds only to the GLP-1 R in the beta cell with high affinity (~5 nM) 
(Xiao et al., 2001). A study investigating the binding affinity of GLP-1 analogues 
modified at various positions within the peptide structure has revealed significant 
reductions in binding affinity when essential amino acids listed above in the bl­
and C-terminus were modified (Adelhorst et al., 1994). Upon activation, GLP-1 
and GLP-1 R are internalized into the beta cell as an intact ligand-receptor 
complex; radiolabeled GLP-1 can, therefore, emit a signal from within the beta 
cell and provide an accurate indication of beta cell mass
GLP-1 has at least three elimination mechanisms: renal clearance, hepatic 
clearance and degradation by the plasma enzyme DPP-IV in the blood (Kieffer & 
Francis Habener, 1999). Rapid enzymatic cleavage makes GLP-1 inactive in less 
than five minutes. As a result, GLP-1 modifications that render the peptide 
resistant to DPP-IV cleavage are necessary to facilitate in vivo imaging of beta 
cells. The most crucial site for peptide modification is the position-two alanine, 
referred to as 2Ala, of bioactive GLP-1, where peptide cleavage takes place. It 
has been shown that changing the steric conformation of GLP-1 by substituting 
2Ala with D-Ala results in a 10-fold lower rate of degradation by DPP-IV 
compared to GLP-1 (7-36) amine (Siegel et al., 1999). Therefore, D-Ala was 
selected as the most suitable modification to resist DPP-IV degradation in 
plasma for our GLP-1 analogues.
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Figure 1 a & b. GLP-1 Modification Sites and Imaging Probe Schematic
(A) Modifications were made to the native GLP-1 structure to resist enzymatic 
degradation and to carry an imaging isotope. Each letter represents the 
abbreviation of an amino acid as outlined by the International Union of Pure and 
Applied Chemistry (IUPAC). (B) A targeted imaging probe schematic contains 
two components: a targeting component and a radioisotope for nuclear imaging. 
Peptides, such as GLP-1, are often used at targeting components because they 
are relatively small and can be modified.
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1.3.3 Imaging Technologies
Selection of an appropriate imaging modality is crucial to enable non-invasive 
beta cell mass estimation. Several imaging techniques exist, each with their 
unique advantages and limitations. Bioluminescence imaging, magnetic 
resonance imaging, single photon emission computed tomography (SPECT) and 
positron emission tomography (PET) are a few of the imaging techniques that 
have been employed to facilitate beta cell targeting and imaging (Table 1). A 
focus on the strengths of SPECT and PET will rationalize the development of 
radiolabeled compounds (radiotracers) for beta cell imaging.
1.3.4 SPECT and PET Imaging of the Beta Cells
Currently, the only method that can directly determine beta cell mass is 
extremely invasive and impractical: a biopsy of the pancreatic tissue to directly 
measure beta cell area and volume using image analysis software (Meier et al., 
2009). Nuclear medicine-based imaging involves the administration of a 
radiotracer that specifically targets and provides diagnostic information about 
biological processes in vivo (Cherry, Sorenson, & Phelps, 2003). Detectors 
situated around a sample or patient can detect gamma rays emitted from a 
decaying radiotracer and ultimately provide tomographic images of the 
distribution of the radiotracer in the body. SPECT imaging involves the detection 
of gamma rays emitted from the radioactive decaying nuclei of isotopes such as 
111ln and " mTc. Collimators are specific to SPECT systems and serve as a 
focusing system for the gamma camera; only gamma rays traveling parallel to 
the collimators are detected. The detection system is a scintillation crystal that
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absorbs the gamma ray and converts it into a photon that is subsequently 
amplified by photomultiplier tubes (PMT) into a signal that can be converted 
electronically. A computer can generate 3D images that correspond to the 
radiotracer’s distribution and its energy based on the signals from the PMT. PET 
systems do not have collimators because of the unique character of decaying 
PET radioisotopes such as 18F or 68Ga. Two antiparallel photons with equal 
energy (511 keV) are emitted as products of the annihilation between a positron 
and an electron released from a decaying PET radioisotope; as such, PET relies 
on the detection of coincident 511 keV gamma rays to localize the radiotracer’s 
position. Due to their relatively longer half-lives, SPECT radioisotopes are widely 
accessible because they can travel longer distances and reach remote areas. 
PET radioisotopes typically require access to a nearby cyclotron or generator, 
since their half-lives are generally shorter. Several GLP-1R probes have been 
developed for use with nuclear imaging and have certainly displayed advantages 
over other imaging technologies that will be discussed (summarized in Table 1).
The pancreatic islets range in size from 50 to 300 pm in diameter, making the 
beta cell a small target for imaging and corroborating the need for an imaging 
modality with high sensitivity (Morini et al., 2006). Bioluminescence is an imaging 
modality that provides good tissue attenuation to a certain depth, is highly 
sensitive and can be quantified. One study employed bioluminescence to track 
islets transplanted under the renal capsule of mice and quantified the in vivo 
bioluminescence by means of photon counts (Fowler et al., 2005). Astonishingly, 
the correlation between the number of transplanted islets and the
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bioluminescence was high (R2 = 0.9946), therefore confirming bioluminescence 
as a useful tool to quantify beta cell mass. One important caveat associated with 
bioluminescence is its poor depth penetration of about a few centimetres, making 
imaging of human beta cells in vivo impossible; therefore, it cannot be 
implemented clinically, especially to follow beta cell mass during diabetes 
progression.
The sensitivities of PET and SPECT lie within the range of nM to pM which is 
relatively higher than MRI which can detect amounts in the M to mM range 
(Cherry et al., 2003). One group using 111ln-exendin-4 was able to detect GLP- 
1R expressed in the pancreata of mice using SPECT (Gotthardt et al., 2006). 
Another group, using 68Ga-exendin-3, was able to detect small tumours (2-5 mm 
in diameter) in the pancreata of mice imaged with PET (Brom, Oyen, Joosten, 
Gotthardt, & Boerman, 2010). Although MRI has inferior sensitivity than PET and 
SPECT, it does have better spatial resolution. Consequently, MRI has been used 
to track islets labeled with superparamagnetic iron oxide particles (SPIOs) that 
were transplanted under the kidney capsule (Evgenov, Medarova, Dai, Bonner- 
Weir, & Moore, 2005). T2-weighted MR images displayed regions of signal void 
that corresponded to the islet grafts; the volume of this region correlated well with 
the number of islets transplanted (R2 = 0.986) (Evgenov et al., 2005). One 
problem with using SPIOs is that it is difficult to distinguish between tissues that 
naturally present as signal voids in MR images and tissues containing the 
contrast agent. Additionally, SPIOs cause a ‘blooming effect’ in MR images which 
diminishes MRI’s superior spatial resolution. It is clear that sensitivity plays a
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particularly crucial role when attempting to detect small changes in beta cell 
mass; SPECT and PET both have sufficient sensitivity.
The selection of an appropriate imaging modality must also take spatial 
resolution into account. The beta cells must be correctly localized so that 
changes in mass can be monitored. Although SPECT and PET have good spatial 
resolution, that of SPECT is slightly higher due to the fact that the resolution of 
PET depends on the radionuclide used and its ‘effective positron range’. PET 
radionuclides emit a positron that travels between 0.1 and 2 cm away from its 
nucleus before it annihilates with an electron. The effective positron range for 18F 
is 2.5 mm, while that for 68Ga is 7.7 mm (Cherry et al., 2003). PET may not have 
sufficient spatial resolution to visualize individual beta cells; however, it is 
certainly capable of imaging clustered beta cells in islets and insulinomas. Co­
registration of PET and CT images taken of BALB/c nude mice with 
subcutaneous beta cell tumours in the hind-limb confirmed the signal emitted 
from the tumours was, in fact, localized to the hind-limb (Brom et al., 2010). 
Similarly, positive colocalization was observed between the SPECT signal and 
insulinomas in the pancreas imaged with MRI (Gotthardt et al., 2006). Thus, PET 
and SPECT can be used to accurately distinguish signal in the pancreas from 
any signal in the surrounding organs, especially when a targeted probe is used. 
The combination of PET or SPECT with MRI or CT can further aid in localizing 
the emitted signal.
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A benefit of using PET is the ability to quantify radiotracer uptake in a particular 
tissue. The standard uptake value (SUV) is a calculation of the concentration per 
total injected dose for a given body weight at a given time for a particular region 
of interest (ROI) (Thie, 2004). The SUV was shown to be useful in a study that 
successfully correlated blood glucose concentrations with 11C-labeled radiotracer 
uptake in the pancreata of rats that spontaneously developed diabetes (Souza et 
al., 2006). Blood glucose concentration is not an accurate indicator of beta cell 
mass; correlating the SUV with actual beta cell mass is a better approach. Our 
lab has recently used PET to quantify beta cell mass by measuring 18F-FHBG 
uptake in beta cells expressing the sr39tk reporter gene (McGirr et al., 2010). A 
significant correlation was found between 18F-FHBG uptake in C57BL/6 mice and 
beta cell mass (R2 = 0.8) determined in vitro by histomorphometric 
measurements of pancreatic tissue sections.
Both SPECT and PET seem to serve as ideal imaging modalities to image the 
beta cells in vivo due to their high sensitivity, good spatial resolution and ability to 
quantify probe uptake in the pancreas. To facilitate radiolabeling of peptides, 
metal chelators are often employed to carry a radionuclide. One commonly used 
chelator for targeted-peptide coordination with radionuclides is N°- 
diethylenetriaminopentaacetic acid (DTPA) which is typically used to stably 
coordinate exendin-3 and exendin-4 to 111 In in beta cell imaging research (Brom 
et al., 2010; Wild et al., 2006). GLP-1R-targeted probes increasingly require a 
chelator that can facilitate both PET and SPECT radionuclide attachment; the
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator can
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facilitate both 68Ga and 111 In coordination (Brom et al., 2010; Wild et al., 2010). 
DTPA has not been shown to serve a similar function. In our previous 
publication, DOTA -  a cyclen derivative -  was selected as the best chelator due 
to its inertness and thermodynamic stability when coordinated with 68Ga and 111ln 
(Behnam Azad, Rota, Breadner, Dhanvantari, & Luyt, 2010).
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Modality SpatialResolution Sensitivity Quantitative
Clinical
Translation
MRI pm M to mM No Yes
PET mm nM to pM Yes Yes
SPECT mm nM to pM Yes Yes
Bioluminescence mm nM to pM Yes No
Table 1. Features of Imaging Modalities Commonly Used to Image the Beta 
Cells
The four imaging modalities commonly used to image the beta cells are listed. 
Spatial resolution, sensitivity, quantitative ability, and clinical translatability are 
compared for each modality. PET and SPECT were selected as the ideal 
imaging modalities.
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1.3.5 Imaging Beta Cells in vivo
Several review papers on beta cell imaging will offer a catalogue of biomarkers 
that have been identified and probes that have been developed (summarized in 
Table 2); so far, none of the technologies having-success in quantifying beta 
cells have been implemented clinically (Moore, 2009; Souza et al., 2006; Wu & 
Kandeel, 2010). The most promising biomarker for beta cell imaging thus far has 
been the GLP-1R and is reflected in the number of probes that have been 
developed to target it. While GLP-1 is the natural ligand of GLP-1R, another 
family of peptides, the exendins, have also been identified as agonists (exendin-4 
and exendin-3) and antagonists (exendin [9-39] amide) of GLP-1 R (Goke et al., 
1993).
Exendin-4, a bioactive peptide isolated from the venom of Heloderma suspectum 
shares 53% sequence homology with GLP-1, binds to the GLP-1 R with high 
affinity, and has the ability to stimulate insulin secretion in a glucose-dependent 
manner (Goke et al., 1993). Exendin-3 and exendin-4 differ by 2 amino acids at 
the N-terminus; furthermore, exendin-3 has been shown have a high affinity for 
the GLP-1 R and undergoes GLP-1 R-mediated internalization in beta cells (Brom 
et al., 2010). Radiolabeled exendin-4 -  aimed to target GLP-1 R for in vivo 
imaging -  has been used extensively for SPECT and PET imaging of 
insulinomas in both mice and humans (Wicki et al., 2007; Wild et al., 2006; Wild 
et al., 2010). Targeted exendin-based probes for PET and SPECT imaging have 
proven to be specific to the beta cells, and facilitate quantitative beta cell mass
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estimation; however, only quantitative analyses of beta cell tumour mass have 
been pursued using these probes. This is because beta cell tumours express the 
GLP-1R in high density and provide a much larger target for imaging. To our 
knowledge, none of the targeted probes listed above -  or any other in the 
literature -  has been able to successfully image the euglycemic beta cells in situ.
Thus, this project aimed to characterize novel 111 In- and 68Ga-labeled GLP-1 













Wild et al., 2006






Target: Type 2 vesicular 
monoamine transporters 
(VMAT2)
Souza et al., 2006
Bioluminescence
Pancreatic islets expressing 
firefly luciferase and green 
fluorescent protein (GFP) 
under the control of the 
cytomegalovirus (CMV).
Fowler et al., 2005
Table 2. Current Methods Used to Quantify Beta Cell Mass
This table outlines the four prominent methods used to enable beta cell mass 




A GLP-1 analogue would be identified as a suitable probe to measure beta cell 
mass in vivo with PET or SPECT based on several factors: its specificity for the 
GLP-1 R, its binding affinity for the GLP-1 R, and its ability to be imaged and 
facilitate quantification of beta cell mass in vivo.
1.5 Objectives
1. Characterize a library of novel modified GLP-1-based analogues in vitro 
by determining their binding affinity, biological activity and serum stability.
2. Select the GLP-1 analogue with the highest binding affinity to perform in 
vitro imaging.
3. Use the GLP-1 analogue with the highest binding affinity to image beta 
cells in vivo using pSPECT or pPET, and to quantify probe uptake in the 
pancreas defined by a region of interest.
4. Determine the uptake of radiolabeled GLP-1 analogue in the pancreas as 
well as surrounding organs and those known to express the GLP-1 R.
All GLP-1 conjugates were synthesized, radiolabeled and HPLC analyzed by






Abbreviations for the synthesized GLP-1 analogues are used throughout this 










Table 3. List of Analogue Abbreviations and Peptide Structure
2.2 Binding Assays in a GLP-1 R-expressing Cell Line
Receptor binding assays were conducted to determine the half-maximal 
inhibitory concentration (IC5 0) of each analogue and native GLP-1 in triplicate 
according to a previously published method (Xiao et al., 2001). Chinese hamster 
ovary cells stably expressing the recombinant GLP-1 R (CHO/GLP-1R) were 
cultured in high-glucose (4,500 mg/L D-glucose) Dulbecco’s Modified Eagle's
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Medium (DMEM) (Invitrogen) containing 10% fetal bovine serum (FBS) and were 
selected using G-418, an antibiotic. Assays were performed on cells passaged 
no more than 10 times. On the day of the assay, cells were washed 2x with warm 
Hank’s buffered salt solution (HBSS) and detached using 2mM 
Ethylenediaminetetraacetic acid (EDTA) in HBSS. One million cells were 
incubated with 200 pi volume containing three components: (a) a range of 
concentrations (10'5 to 10"11 M) of unradiolabeled GLP-1 analogues (compounds 
1 through 8); (b) 0.77 pmol [125l]Exendin (9-39) (PerkinElmer, Shelton CT), and 
(c) binding buffer (DMEM containing 0/1% Trasylol [Bayer, Wayne NJ] and 0.1% 
Bovine serum albumin (BSA) [Sigma-Aldrich, St. Louis MO, pH 7.4]. Following 
incubation, cells were centrifuged at 2800 rpm for 15 min. Cells were then 
washed with cold binding buffer before a final centrifugation. Cell pellets were 
placed in a gamma well counter and results were used to generate a binding 
curve. Tables and IC50 calculation were performed on MS Excel 2007.
2.3 In v itro  Displacement
INS-1 832/13 cells (a gift from Dr. Christopher B. Newgard, Duke University) are 
derived from a rat insulinoma that have been stably transfected with a plasmid 
coding for the human proinsulin gene (Hohmeier et al., 2000). Cells were 
incubated in a 6-well plate at a density of one million cells per well for 48 hrs. On 
day of assay, cells were rinsed 2x with warm HBSS and incubated with binding 
buffer (DMEM, 1 % BSA, and 0.1 % Trasylol, pH 7.4) for 30 min. Following 
incubation, cells were incubated for 30 min at 37° C with: (a) binding buffer and 1 
% dimethyl sulfoxide (DMSO) alone, (b) 0.1 MBq [111ln]-8, or (c) 0.1 MBq [111ln]-8
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and excess (1 pM) unradiolabeled exendin (9-39). After the incubation period, 
media was removed, cells were rinsed twice with cold HBSS and covered with 
500 pL culture media. Cells were imaged for 30 min with a Siemens Symbia T6 
gamma camera using a medium-energy general purpose collimator with parallel 
slits. Images were acquired and analyzed using GE Xeleris software.
2.4 cAMP Radioimmunoassay
To confirm receptor activation, intracellular [cAMP] was measured in CHO/GLP- 
1R cells using a cAMP radioimmunoassay (RIA) kit (PerkinElmer, Shelton, CT). 
Radioimmunoassays were conducted to measure intracellular cAMP 
accumulation following peptide stimulation according to (Inwin et al., 1997). 
CHO/GLP-1R cells (-100,000 cells/well) were cultured in a 24-well plate 48 hrs 
before assay. On the assay date, cells were washed twice with 37° C HBSS and 
then incubated for 30 min at 37° C with assay buffer (DMEM, 0.4% glucose, 1% 
BSA, pH 7.4). Cells were then incubated for 30 min with varying concentrations 
of peptide (10"6 to 10'10 M) and 1 mM isobutylmethylxanthine (IBMX) along with 
assay buffer to a volume of 500 pi. Following incubation, cells were washed twice 
with cold HBSS, lysed using 80% cold ethanol on ice, collected using a rubber 
cell scraper and transferred to a glass tube for storage. Peptides were stored in a 
-80° C freezer no longer than 48 hrs. On the day of assay, cell components were 
thawed at 4° C and cAMP RIA was conducted according to manufacturer’s 
instructions. Receptor activation of select peptides was assessed by calculating 
the half maximal effective concentration (ECso)- The [cAMP] accumulation 
following stimulation with increasing concentrations of peptide was calculated as
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a percent of the maximum binding for each peptide (i.e. [cAMP] at 10"6 M 
stimulation). The EC50 was calculated by determining the equation of a line 
between the points greater and smaller than 50% and determining the 
concentration of peptide at EC5o = 50% using GraphPad Prism version 5 (San 
Diego, CA, www.graphpad.com). A One-way ANOVA was conducted to 
determine whether the IC5o values for each peptide were significantly different 
from one another using SPSS Statistics V 17.0.
2.5 Serum Stability
Serum stability studies were conducted to assess the stability of compound 7 
following DAIa8 modification according to previously published procedures (Ritzel 
et al., 1998). Briefly, GLP-1 (7-36) amide (Bachem) and compound 7 (1 pg/pl 
peptide in acetate buffer, pH 6.2) were incubated with rat plasma (final sample 
volume 1 ml; final peptide concentration 20 pM) for 0.5, 2, 4 and 6 hrs at 37 °C. 
The incubation period ended with the addition of 40 pL aqueous 10% 
trifluoroacetic acid (TFA). Samples were then applied to C18 reverse-phase 
cartridges (Light C18 sep-pak©), washed with 4 ml aqueous 0.1 % TFA, and 
eluted with 2 ml 60% acetonitrile in aqueous 0.1% TFA. After lyophilization, 
samples were analyzed using analytical reverse phased high pressure liquid 
chromatography (RP-HPLC) (Grace Vydac Protein/Peptide RP-C18 column 4.6 x 
250 mm, 5 pm) (Behnam Azad et al., 2010). The half lives of the peptides were 
determined using GraphPad Prism version 5.
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2.6 In vivo  pSPECT Imaging
C57BL/6 mice were scanned under 2% isoflurane anaesthesia for 30 min, 1 hr (n 
= 1) and 4 hrs (n = 2) post-injection (P.l.) of 111ln-7. Mice were injected 
intravenously with 37 or 18.5 MBq 111 ln-7 1 h or 4 hrs before imaging using an 
explore speCZT small-animal SPECT scanner (GE Healthcare, London ON) 
according to parameters used by (Tai et al., 2008). The scanner uses a 10-head 
stationary ring of solid-state cadmium zinc telluride (CZT) detectors for increased 
scan speed and sensitivity. An 8-slit collimator was used with a field of view of 32 
mm transaxially and 78 mm axially. With the full ring detector, 360° of data were 
acquired by rotating the collimator 45° (45 steps, 17step). During acquisition, 
300,000 counts per step were acquired in list mode, using an energy window of 
51-250 keV. The SPECT images were reconstructed using the OSEM iterative 
algorithm into a 128 x 128 x 32 array with a voxel size of 0.25 x 0.25 x 2.46 mm. 
Reconstructions for 111ln were generated independently. The sum of the counts 
between 166 -180 keV and 205 - 215 keV was used fo r 111 In. Three-dimensional 
image reconstructions were viewed in MicroView (GE Healthcare) to localize the 
111ln signals.
2.7 E x vivo  SPECT Imaging
The pancreata of mice that were imaged in the pSPECT scanner were removed 
immediately after imaging, rinsed in phosphate buffered solution (PBS) and 
imaged with a gamma camera to better visualize probe signal in the pancreas. 
Planar ex vivo images were acquired with a Siemens Symbia T6 gamma camera
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with matrix size 128 by 128 pixels, using a medium-energy general purpose 
collimator. The heart, pancreas and liver were set upon a stationary gamma 
camera head and a 30 min acquisition took place. Images were acquired and 
analyzed using GE Xeleris software. Regions of interest (ROIs) were drawn and 
the counts/pixel for each ROI was calculated by dividing the total number of 
detected counts by the camera divided by the total pixel area of the ROI.
2.8 |jPET Image Acquisition and Analyses
A gallium-68 generator with a decaying germanium-68 source and a pPET 
imaging system were readily accessible to us on-site at the Lawson Health 
Research Institute. This enabled us to conjugate 68Ga-analogues and perform 
pPET imaging on-site. On the day of imaging, mice were anesthetized with 3% 
isoflurane using a sealed nose cone that provided a constant flow of a mixture of 
air and 1.5% isoflurane during scanning. Each mouse was injected via tail vein 
catheter with 2.1 -  17.8 MBq of 68Ga-7 or acylated 68Ga-7, and placed on the 
scanner bed of a General Electric Healthcare Explore Vista Dual-Ring PET 
scanner, which provides an 8 cm (diameter)* 4.6 cm (axial) field of view, a voxel 
size of 3.9 mm3, and a full-width half-maximum (FWHM) between 1.9 and 2.2 
mm. A dynamic scan was acquired for 1 h, during which images were obtained 
every 3 min for the first 15 min, and every 5 min thereafter. A 30 min static scan 
was then acquired 4 hrs P.l. Subsequent attenuation, dead time, random and 
scatter coincidence corrections were performed on PET images before they were 
reconstructed using three iterations of ordered subsets-expectation 
maximization. The software supplied with the scanner, Explore Vista 3.1, was
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used for image acquisition and reconstruction. The standard uptake value (SUV) 
could not be calculated since a clear delineation of the pancreas was not 
possible.
2.9 Biodistribution of Radiolabeled GLP-1 Analogues 
in CD1 and C57BL/6 Mice
All mice were treated in accordance with the guidelines set out by the Animal 
Use Subcommittee of the Canadian Council on Animal Care at the University of 
Western Ontario. In vivo probe uptake was assessed in CD1 and C57BL/6 mice. 
Mice were anaesthetized under 2 % isoflurane during tail vein catheter insertion, 
injection and during cervical dislocation. CD1 mice (20-28 g, 6-8 wks of age) 
were administered 0.2 -  3.2 MBq of radiolabeled probe alone or with 1 mM 
unradiolabeled exendin (9-39) (Bachem) for blocking studies. C57BL/6 mice (17- 
23 g, 6-8 wks of age) were injected with 0.8 - 4.4 MBq of radiolabeled probe 
alone or co-injected with 1 mM unradiolabeled exendin (9-39) for blocking 
studies. Mice were sacrificed at 3 min and 4 hrs P.l. The pancreas and other 
organs of interest were excised, weighed, and washed once in cold PBS before 
radioactivity was counted in a high-purity Ge gamma counter (Ortec GWL-190- 
15-S, detection range 51.32-2111.36 keV at 1.4-2.3 keV resolution, linear range 
of detection 0 -  4030 Bq) at various time points following intravenous (I.V.) 
injection of each radiolabeled compound. Activity of the samples was determined 
with an energy window of 507.94 -  515.85 keV for 68Ga (energy of 68Ga is 511 
keV) and 162 -  177 and 242 -  248 keV fo r 111 In (energies o f 111 In are 171 and 
245 keV). To ensure all activity was captured accurately, samples were counted
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to a dead time between 1 and 5%. The amount of radioactivity in each tissue was 
calculated as Bq/g tissue and decay corrected to the time of injection. Probe 
uptake was calculated as percent injected dose per gram (%ID/g) tissue. To 
determine specific uptake, mice were co-injected with 1 mM unradiolabeled 
exendin (9-39) and 68Ga-7. A One-way ANOVA was performed to determine if 





3.1 In vitro  Characterization of GLP-1 Analogues
Note: All GLP-1 conjugates were synthesized, radiolabeled and HPLC analyzed 
by Babak Behnam Azad.
3.1.1 Receptor Binding Assays
Receptor binding assays were conducted to determine the binding affinity of the 
novel GLP-1 conjugates. Nine GLP-1 conjugates plus native GLP-1 were tested, 
and half-maximal inhibitory concentration (IC50, in nM) values were calculated as 
outlined in Table 4. The conjugates modified at positions Lys22 and Lys37 
displayed the strongest binding affinities, in that their IC50 values were closest to 
that of native GLP-1 (Table 4). GLP-1 conjugates with an IC50 within an order of 
magnitude of that of native GLP-1 (i.e. less than 100 nM) were considered 
suitable probes for further in vitro and in vivo characterization. We therefore 
selected compounds 2, 7 and 8 for further in vitro characterization and in vivo 




Structure IC50 (nM) EC50 (nM)
GLP-1 (native) 5.0 ±0.1 0.04 ± 0.02
1 22Lys-ln-DOTA-GLP-1 (7-36) 598 ± 45 -
2 22Lys-AEEA-ln-DOTA-GLP-1 (7-36) 93 ± 7 * 0.74 ± 0.07
3 26Lys-ln-DOTA-GLP-1 (7-36) 970 ± 73 -
4 26Lys-AEEA-ln-DOTA-GLP-1 (7-36) 2660 ± 129 -
5 34Lys-ln-DOTA-GLP-1 (7-36) 268 ± 16 -
6 34Lys-AE EA-I n-DOT A-G LP-1 (7-36) 573 ± 39 -
7 37Lys-ln-DOTA-GLP-1 (7-37) 63 ± 4 * 0.78 ± 0.07
8 37Lys-AEEA-ln-DOTA-GLP-1 (7-37) 89 ± 3 * 0.93 ± 0.05
Table 4. Receptor binding and cAMP measurements for novel GLP-1 
analogues
The receptor binding affinities (IC5o) and cAMP activation (EC5o) were determined 
for eight novel GLP-1 analogues. Compounds 2, 7 and 8  had IC50S nearest that 
of native GLP-1 and were therefore chosen for cAMP activation studies (marked 
in asterisks). A One-way ANOVA was conducted on the EC50 values; no 
significant difference was observed between the peptides (p = 0.09, ns).
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3 .1 .2  cAMP Radioimmunoassay
The GLP-1R is a B-class G-protein-coupled receptor (GPCR) which, upon 
activation, stimulates 3'-5'-cyclic adenosine monophosphate (cAMP) production 
via adenylate cyclase (Buteau, 2008). Thus, changes in cAMP production can 
confirm the biological activity of GLP-1 analogues. To assess GLP-1 receptor 
activation by the 3 analogues with the most favourable binding affinities, 
intracellular cAMP concentrations were measured in CHO/GLP-1R cells in the 
absence and presence of peptide stimulation. Three GLP-1 analogues with IC50S 
within an order of magnitude of native GLP-1 (i.e. 2, 7 & 8) were assayed. The 
EC50 was calculated using the equation of a straight line between the points that 
surrounded approximately 50% of the maximum stimulation for each peptide 
(Equations 1-4). A One-way ANOVA was conducted to determine whether the 
EC50S were significantly different from one another and, in particular, from native 
GLP-1 (Table 4). Although the analogues displayed higher EC5o values than 
native GLP-1, the differences were non-significant (F(3,8) = 3.15, p = 0.09, ns).
The cAMP response before and after 10 nM stimulation by the three analogues is 
shown in Figure 3. Following stimulation, native GLP-1 increased cAMP 
formation 33.3 ± 0.3-fold times the basal concentration, which was highly 
significant (p< 0.001). Similarly, compound 8  increased cAMP formation 32.6 ±
y = 9.8 x 1010 (x) + 10.5 
y = 5.4 x 1010 (x) +9.8 
y = 3.4 x 108(x) +43 






1.0-fold (p<0.001) from basal. Compounds 7 and 2 significantly increased cAMP 
formation 13.8- and 14.4-times from basal, respectively (p< 0.05).
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Figure 2. cAMP Dose Response Curves
cAMP accumulation was measured in CHO/GLP-1R cells following stimulation 
with increasing concentrations of native GLP-1 or compound 2, 7 or 8. Each point 
represents cAMP measurements as a percent of the total binding for that 
analogue. Dose-response curves were generated to fit the data points for better 





■  10 nM Stimulation
Native GLP-1 Compound 2 Compound 7 Compound 8
Figure 3. cAMP Measurements at Basal and Following 10 nM Stimulation
In vitro cAMP accumulation in CHO/GLP-1R cells at basal level (white bars) and 
following stimulation (black bars) with 10 nM native GLP-1, compound 2, 7 or 8. 
Bars represent means ± SEM (n = 3 for each peptide). **p < 0.001, *p < 0.05.
3.1.3 In vitro Validation of GLP-1R Binding in a Beta Cell Line.
After having determined receptor binding affinity and activation, we validated 
receptor binding of one of the analogues in vitro in INS-1 832/13 cells, a beta cell 
line that expresses GLP-1R, using gamma camera scintigraphy. Cells were 
incubated with 0.1 MBq compound 8 alone or in the presence of excess (1 pM) 
exendin (9-39) to determine specific binding in vitro. A receptor binding assay 
was conducted to confirm the specificity of compound 8 for the GLP-1R. When 
INS-1 832/13 cells were incubated with 111 ln-8 alone, regions of strong signal 
intensities were detected using a stationary gamma camera (Figure 4). In 
contrast, the of excess exendin (9-39) blocked 111 ln-8 binding to the cells and 
resulted in a dramatic reduction in signal intensity (Figure 4), thereby confirming 
GLP-1 R specificity.
3.1.4 Serum Stability of Compound 7
Serum stability was assessed in native GLP-1 and compound 7 to determine 
whether the D-Ala configuration and addition of the DOTA chelator affected the 
analogue’s stability in vitro. Twenty pM of either native GLP-1 or compound 7 
was incubated in rat serum for various time points, and after solid-phase 
extraction, analyzed using RP-HPLC. An exponential decay curve was generated 
for compound 7 (Equation 5) and native GLP-1 (Equation 6) in Figure 5.
y = 100e"° 05t 





Where ‘y’ and ‘t ’ represent the proportion of remaining peptide (%) and time (hrs), 
respectively. Based on their equations, compound 7 obtained a half-life of 13 hrs 
and native GLP-1 a half-life of 15 min.
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Cells only Cells + 8 Cells + 8 + Ex-4
Figure 4. In  v itro  Receptor Displacement Study
To confirm specific binding, INS-1 cells were incubated with PBS (1 & 2), 0.1 
MBq 111 ln-8 (3 & 4), or 0.1 MBq 111 ln-8 and 1 pM cold exendin (9-39) (5 & 6). 
Radioactivity was measured using a gamma camera and the results are 
quantified in the graph. Bars represent the mean (n = 2).
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Figure 5. Serum Stability of Compound 7 in  v itro
Stability of compound 7 was assessed in vitro by incubating 20 pM of peptide in 
rat serum for 0, 0.5, 2, 4 and 6 hrs. Samples were HPLC-analyzed at each time 
point and the area under the curve (AUC) for the peak corresponding to the GLP- 
1 analogue was calculated. Data points represent the ratio of the AUC at each 
time point to the AUC at 0 hrs. Equations were derived for each decay curve; 
half-lives were calculated for compound 7 and native GLP-1 as 13 hrs and 15 
min, respectively.
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3.2 In vivo  Validation o f 111 In- and 68Ga-labeled GLP-1 
Analogues
3.2.1 Biodistribution of 111ln-2
A biodistribution assay was conducted at both 4 and 24 hrs in C57BL/6 mice to 
determine the ideal time point at which uptake of 111 ln-2 was highest in the 
pancreas. The percent injected dose per gram (% ID/g) tissue was determined in 
several organs including the pancreas at 4 and 24 hrs (Figure 6).
At 4 hrs, pancreatic uptake o f 111 ln-2 was 4.0 ± 2.0 % ID/g tissue, second only to 
the heart with 4.7 ± 3.3 % ID/g tissue. Tissues surrounding the pancreas such as 
the spleen, liver, gut and kidneys displayed relatively low probe uptake at 4 hrs 
(1.5 %, 0.1 %, 0.1 %, and 0.5 % respectively).
At 24 hours, probe uptake in the pancreas remained constant around 4%; 
however, surrounding tissues such as the spleen, liver and kidneys displayed 
higher probe uptake than the pancreas. Therefore, 4 hrs was determined to be a 











Figure 6. Biodistribution of 111ln-2 in C57BL/6 Mice at 4 hrs and 24 hrs Post- 
Injection (P.I.).
C57BL/6 mice were injected with 111 ln-2 and organs were counted in a gamma 
well counter 4 hrs and 24 hrs P.l. to determine optimal time for in vivo imaging. 
Uptake was measured as % injected dose per gram (% ID/g) tissue. Error bars 
represent mean ± SEM. (/? = 3).
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3.2.2 Tissue-specific Uptake of 111ln-7 at 4 hrs
To determine specific binding of the 111 In-labelled probe in the pancreas, 
biodistribution assays were conducted in C57BL/6 mice at 4 hrs P.l. of 111ln-7 
alone or together with excess (1 mM) unlabeled exendin (9-39). Specificity was 
confirmed when probe uptake was blocked in the presence of unlabeled exendin 
(9-39), reflected by differences that were significant (p<0.05) or highly significant 
(p<0.01) in Figure 7.
A highly significant difference was confirmed in the pancreas after it dropped 
from 1.3 ± 0.1 % to 0.0 ± 0.0 % (p< 0.01) with co-administration of exendin (9- 
39). The lungs, gut, heart and kidneys also displayed significant specific uptake 
at 4 hrs.
3.2.3 pSPECT in vivo Imaging
Three C57BL/6 mice were scanned in a pSPECT system 1 hr or 4 hrs P.l. of 18.5 
or 37 MBq 111 ln-7. The scan duration was 20 -  40 min for SPECT and 10 min for 
CT. Images were reconstructed and co-registered; however, only the SPECT 
images could be recovered from the system. SPECT images revealed high signal 
intensity in the kidneys (Figure 8).
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Figure 7. Biodistribution of 111ln-7 in C57BL/6 mice 4 hrs P.l.
C57BL/6 mice were injected with either 111 ln-7 alone or 111ln-7 with 1 mM cold 
exendin (9-39) to determine if uptake was specific to the pancreas. Organs were 
counted in a gamma well counter 4 hrs P.l. Uptake was measured as % injected 
dose per gram (% ID/g) tissue. Bars represent means ± SEM (n = 3). *p< 0.05; **
p<0.001.
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Figure 8. SPECT/CT Images of C57BL/6 Mice Following 111ln-7 Injection.
SPECT images were acquired 1 hr (mouse 1 and 3) and 4 hrs (mouse 2) P.l. of 
18.5 MBq (Mouse 3) or 37 MBq (mouse 1 and 2) of 111ln-7 in C57BL/6 mice, 
respectively. The pancreas was not clearly visible at either time point; however, 
the kidneys displayed high signal intensity at both time points.
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3.2.4 Ex vivo Gamma Camera Imaging of the Pancreas
Based on the biodistribution data, the pancreas had taken up probe at 4 hrs; 
however, this was not reflected during in vivo imaging since the high signal 
intensity in the kidneys quenched any low signal from surrounding organs. To be 
able to visualize the pancreas using SPECT, ex vivo SPECT imaging was 
performed. The pancreas, liver, and heart were excised following pSPECT 
imaging. Organs were placed on a stationary gamma camera head and a static 
image was acquired for 30 min (Figure 9). The images were analyzed 
qualitatively based on signal intensity. The pancreata from the mice administered 
37 MBq displayed the highest signal intensity compared to the pancreas of the 
mouse administered 18.5 MBq. The livers displayed high signal intensity at both 
administered amounts even though they were not visible during the in vivo 
pSPECT scan (Figure 8). The hearts displayed the lowest signal intensity 
comparable to background.
3.2.5 Dynamic in vivo |jPET imaging of CD1 mice
We then labeled our analogue with 68Ga to enable PET imaging of the pancreas. 
CD1 mice are suitable for long-term diabetes studies because they do not 
develop glucose intolerance like male C57BL/6 mice do; thus, CD1 mice were 
used for this imaging study. To determine the optimal time at which in vivo 
imaging and biodistribution should be conducted, a 1 hr dynamic pPET scan was 
performed in CD1 mice immediately following administration of 17.8 MBq of 
68Ga-labeled probe. In addition, a static scan was conducted for 20 min, 4 hrs
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P.l.) (Figure 10). The pancreas was not clearly visible upon qualitative 
observation; however, an area with scattered low signal intensity was observed 
above the left kidney in the region of the pancreas between 3 and 9 min (red 
arrow, Figure 10). After 3 min, the kidneys began to accumulate the peptide and 
quench the signal from any surrounding tissues accumulating the probe. At 1 hr, 
kidney retention was still visualized and at 4 hrs, the kidney and bladder (yellow 
arrow) were visible. Therefore, 3 - 5  min P.l. was deemed to be a suitable time 
window at which in vivo imaging should be conducted.
3.2.6 Dynamic in vivo pPET imaging with C57BL/6 mice
The same dynamic scan above was conducted in C57BL/6 mice to observe any 
species differences in 68Ga probe uptake over 1 hr and at 4 hrs P.l. Mice were 
injected with 3.6 MBq of 68Ga-7. No species differences were observed in Figure 
11. The pancreas was not clearly visible; however, a diffuse area of signal 
intensity above the left kidney could be visualized as in Figure 11.
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Figure 9. E x  v ivo  Gamma Camera Image of Liver, Pancreas and Heart.
Three C57BL/6 mice were injected with 37 MBq (a & b) or 18.5 MBq (c) o f 111 ln-7 
and sacrificed at 1 hr (A) or 4 hrs (B & C) P.l. Liver (red arrows), pancreas 
(yellow arrows) and heart (green arrows) of each mouse were excised and 
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Figure 10. Dynamic jjPET Scan of CD1 Mouse
One CD1 mouse was injected with 17.8 MBq 68Ga-7, followed by 60 min pPET 
dynamic scan. Mouse was also scanned at 4 hrs. Only kidneys (L: left and R: 
right) and bladder (yellow arrow) could be visualized. The pancreas is located 
above the left kidney where diffuse signal intensity could be visualized (red 
arrow) from 3 through 9 min.
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Figure 11. Dynamic pPET Scan of C57BL/6 Mouse
One C57BL/6 mouse was injected with 3.6 MBq 68Ga-7, followed by 60 min 
pPET dynamic scan. Mouse was also scanned at 4 hrs. Only kidneys and 
bladder (see Figure 10 for localization) could be visualized. The pancreas is 
located above the left kidney where diffuse signal intensity could be visualized 
(red arrow) from 3 through 9 min. Values are indicated by the colour scale to the 
left, with a range of 0 to 2189.9 counts.
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3.2.7 Biodistribution of 68Ga-7 in CD1 Mice
Based on the pPET imaging results, it was determined that the optimal time for 
imaging of the pancreas in vivo was 3 - 5  min since a diffuse signal from the area 
of the pancreas was observed (Figure 10). Therefore, a biodistribution assay was 
performed to further examine the uptake of 68Ga-7 in the pancreas at 3-5 min 
compared with other organs of interest (Table 5a). Additionally, I performed a 
biodistribution at 4 hrs P.l. to determine if time was a determinant in probe uptake 
in the pancreas (Table 5a). Mice were either administered 0.2 -  3.2 MBq 68Ga-7 
alone or with 1mM cold exendin (9-39) to determine if uptake in various organs 
was statistically significant (p< 0.05) and, therefore, specific.
At 3 - 5 min, uptake of 68Ga-7 in the pancreas was 17.6 ± 4.8 % ID/g tissue 
(Figure 12). When administered excess exendin (9-39), uptake in the pancreas 
actually increased to 19.7 ±1 .4  % ID/g tissue. No displacement occurred and 
therefore, specific binding could not be confirmed in the pancreas. The lungs 
displayed the highest average uptake of 68Ga-7 at 3 - 5 min with a large SEM 
(Table 5). The lowest uptake was in the brain. Organs surrounding the pancreas 
such as the kidneys and the spleen displayed higher probe uptake than the 
pancreas. None of the organs known to express the GLP-1R such as the brain, 
heart and lungs displayed specific uptake.
At 4 hrs, uptake in the pancreas remained steady at 16.6 ± 9.9 % ID/g tissue 
(Figure 12). In the presence of exendin (9-39), probe uptake decreased to 12.9 ±
7.7 % ID/g tissue; however, the displacement was not significant and therefore,
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non-specific in the pancreas. The highest probe uptake at 4 hrs was observed in 
the kidneys when mice were co-administered exendin (9-39) (Table 5a). Again, 
no other organs known to express the GLP-1R displayed specific uptake at 4 hrs.
3.2.8 Biodistribution of 68Ga-7 in C57BL/6 Mice
We observed large variances in pancreatic probe uptake between CD1 mice 
injected with 68Ga-7. Consequently, specific uptake in the pancreas could not be 
confirmed in CD1 mice and we questioned whether the selection of mouse strain 
was a factor. As a result, I repeated the biodistribution assay in C57BL/6 mice 
with the same protocol as CD1 mice.
At 3 -  5 min, uptake of 68Ga-7 in the pancreas was 13.7 ± 4.5 % ID/g tissue. 
When co-administered exendin (9-39), uptake actually increased to 50.1 ± 35.7 
% ID/g tissue in the pancreas (Figure 12). Specific uptake was not confirmed in 
the pancreas or in any other organs known to express the GLP-1 R. The highest 
uptake was in the kidney following co-administration of exendin (9 - 39).
At 4 hrs, pancreatic uptake of 68Ga-7 decreased from 2.0 ± 0.5 to 0.5 ± 0.2 % 
ID/g tissue with co-administration of exendin (9 - 39); the difference was 
significant (p<0.05) and therefore, specific binding was confirmed in the pancreas 
Figure 12). Additionally, the difference in uptake in the lungs before and after co­
administration of exendin (9 -  39) was significant (p < 0.05) and therefore 
specific as well. The highest uptake was observed in the kidneys when 68Ga-7 
was injected alone.
54
3 min 4 hours
A Non-blocked Blocked Non-blocked BlockedA (n = 6) IIc IIc [n -  3)
Brain 1.92 ±0.35 1.97 ±0.77 0.12 ±0.03 0.16 ±0.08
Heart 17.8 ± 1.59 27.09 ± 1.08 2.55 ± 0.53 1.79 ±0.44
Lungs 455.66 ± 267.14 33.27 ± 10.59 3.54 ± 0.63 5.71 ± 3.99
Stomach 6.29 ± 1.29 5.65 ± 2.35 1.12 ±0.25 1.85 ±0.79
Liver 44.24 ± 15.85 35.95 ± 5.96 4.59 ±1.48 10.70 ±2.25
Pancreas 17.60 ±4.83 19.68 ± 1.43 16.62 ±9.90 12.92 ±7.69
Spleen 38.33 ± 20.28 8.87 ± 0.67 3.29 ± 0.36 12.37 ±3.51
Intestines 9.61 ± 1.17 11.73 ±1.24 3.44 ± 0.66 2.69 ± 0.83





Blood 63.48 ±4.18 — 2.09 ± 0.38
3 min 4 hours
B Non-blocked Blocked Non-blocked Blocked(n=3-6) (n=3-5) (n=4-5) (n=5)
Brain 5.66 ±4.11 2.53 ± 0.85 0.13 ±0.02 0.09 ± 0.03
Heart 32.96 ± 10.53 16.54 ±4.09 1.28 ±0.38 1.11 ±0.51
Lungs 38.04 ±15.53 35.23 ± 11.34 3.40 ± 0.93* 1.16 ±0.25
Stomach 11.34 ±4.81 7.56 ± 1.64 1.19 ±0.22 0.93 ± 0.27
Liver 17.88 ±8.30 110.60 ±73.77 4.24 ± 1.19 5.37 ± 2.09
Pancreas 13.74 ±4.53 50.09 ± 35.74 1.97 ±0.52* 0.52 ±0.17
Spleen 28.15 ±11.01 17.34 ±5.12 1.89 ±0.57 1.97 ±0.71
Intestines 10.69 ±5.14 55.62 ±46.17 3.00 ± 0.99 1.43 ±0.52
Kidneys 138.38 ± 39.82 506.53 ± 377.21
691.43 ± 
221.78 422.20 ± 168.05
Blood 13.04 ±0.63 267.06 ±211.49 1.17 ±0.33 0.31 ±0.15
Table 5 a,b. Biodistribution of 68Ga-7 in CD1 and C57BL/6 mice.
(A) CD1 mice were administered 0.2 -  3.2 MBq of 68Ga-7 alone or with 1 mM 
cold exendin (9-39), and sacrificed at 3 min or 4 hrs P.l. (B) C57BL/6 mice were 
administered 0.8 -  4.4 MBq of 68Ga-7 alone or with 1 mM cold exendin (9-39), 
and sacrificed at 3 min or 4 hrs P.l. Uptake was calculated as % ID/g tissue 
(means ± SEM; n = 3-6 per treatment group). * denotes significance, p< 0.05.
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Figure 12. Uptake of 68Ga-7 in the Pancreas of CD1 and C57BL/6 Mice
Graphic representation of probe uptake in the pancreas of CD1 and C57BL/6 
mice at 3 min and 4 hrs. Data presented in Table 5 a and b. Bars represent 
means ± SEM.
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3.3 Post-Experimental Modifications to Compound 7
In attempt to avert probe retention in the kidneys, compound 7 was modified by 
adding several acyl groups to the peptide’s chain (Acyl-7). This removes some of 
the peptide’s charge thereby preventing the kidney from retaining the probe in
vivo.
Receptor binding assays were conducted for the newly-synthesized acylated 
69/71 Ga-7 and - 8  to determine if the addition of acyl groups affected their binding 
affinities for GLP-1R. The calculated IC50S for acyl-7 (76.0 ± 3.9 nM) and acyl- 8  
(84.6 ± 6 . 8  nM) were similar to their non-acylated counterparts. Thus, the acyl 
groups did not greatly affect their binding affinities.
Preliminary imaging using one C57BL/6 mouse demonstrated less signal from 
the kidneys throughout a 1 hr dynamic scan following injection of 2.1 MBq of 
6 8Ga-acyl-7 (Figure 14). Instead, higher signal intensity was observed in the 
bladder in comparison to mice administered un-acylated compound 7 (Figure 10 
and Figure 11 ). Distribution volume (DV) maps were also generated based on 
the dynamic images to explore the in vivo efflux over 1 hr of compound 7 from: 
(a) plasma to tissue, then (b) to the beta cells (
Figure 15) (Logan, 2000). The DV maps provided little information regarding 
tracer uptake in the pancreas.
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A biodistribution assay was performed at 3 min and 4 hrs to compare uptake of 
acylated 68Ga-7 with 68Ga-7, particularly in the pancreas and kidneys (
Table 6). Although specific uptake analysis could not be performed (exendin [9- 
39] was not administered and sample size was insufficient), high uptake (18.1 % 
ID/g tissue) was observed in the pancreas at 3 min. Uptake in the pancreas of 
one mouse at 4 hrs was 0.8 % ID/g tissue.
At 3 -  5 min, the kidney uptake of 68Ga-acyl-7 was higher than uptake of 68Ga-7 
(215.3 vs. 138.38 ± 39.82 % ID/g tissue, respectively); however, at 4 hrs, kidney 
uptake of 68Ga-acyl-7 was a great deal lower than 68Ga-7 (233.1 vs. 691.43 ± 
221.78 % ID/g tissue, respectively).
Although the results seem promising, further studies are required to make any 
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Figure 13. Receptor Binding Assays for Acylated Compounds 7 and 8
Receptor binding assays were conducted using varying concentrations (1 0 12 to 
10-6 M) of acylated compounds 7 and 8 and CHO/CLP-1R cells. Binding curves 
were generated for each compound and the IC50 were determined for acyl-7 
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Figure 14. One Hour Dynamic Scan of 68Ga-Acyl-7 in C57BL/6 Mice
One C57BL/6 mouse was injected with 2.1 MBq of acylated 68Ga-7 prior to a 1 hr 
dynamic scan. Although kidney accumulation was decreased, the pancreas was 
still not clearly visible upon observation. The bladder begins to accumulate probe 
around the 5 min time point after which accumulation continues. Values are 
indicated by the color scale to the left, with a range of 0 to 2863.9 counts.
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Table 6. Biodistribution of 68Ga-acyl-7 in C57BL/6 Mice.
C57BL/6 mice were administered 3.3 -  3.7 MBq of acylated 68Ga-7 and 
biodistribution assays were performed 3 min (n = 1) or 4 hrs (r? = 2) P.l. Organs 
of interest were excised and activity measured in a gamma well counter. Results 
are expressed in % ID/g tissue. Standard error of the mean was not calculated as 
a result of a small sample size.
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Figure 15. Distribution Volume Maps of 68Ga-acyl-7 in a C57BL/6 Mouse
Distribution volume (DV) maps were generated using images from the 1 hr 
dynamic scan of a C57BL/6 mouse injected with 2.1 MBq of acylated 68Ga-7. 
Thirteen consecutive DV maps were generated in the area of the abdomen at the 
level of the kidneys. Each slice is 0.77 mm thick at the cranial-caudal direction 
(left to right in figure). Values are indicated by the color scale to the left, with a 




This thesis project was aimed at addressing two main objectives: (1) screening 
novel glucagon-like peptide-1 (GLP-1) analogues as potential PET/SPECT 
imaging probes in vitro; and (2) selecting and characterizing a candidate probe 
for preliminary in vivo imaging.
The development of an imaging probe that can accurately measure beta cell 
mass in vivo has the potential to both facilitate early detection of diabetes onset, 
and to follow islet transplant therapy. As a result, several probes have been 
developed to target the beta cells and, inevitably, the GLP-1 receptor (GLP-1 R) 
has emerged as a candidate biomarker. Examples of such probes include 
exendin-3 and exendin-4, both of which are GLP-1 R agonists. My work was 
focused on characterizing a library of novel GLP-1-based analogues that were 
altered to resist enzymatic degradation and chelated to a radioisotope for single 
photon emission computed tomography (SPECT) or positron emission 
tomography (PET) imaging.
4.1 Summary
Three novel GLP-1 analogues were identified as having similar binding affinity to 
GLP-1 R as native GLP-1 with the strongest IC50 being 63 ± 4 nM. An in vitro 
displacement study confirmed specific binding of 111ln-8 to the GLP-1 R, thereby 
confirming its suitability for GLP-1 R imaging in vivo. Modifications to the peptide 
structure of GLP-1 rendered it stable in rat plasma for 13 hrs, verifying its
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suitability for long duration imaging studies. Biodistribution assays with 68Ga-7 
conducted in outbred (CD1) mice demonstrated variable results; however, results 
were more consistent using inbred (C57BL/6) mice and significant uptake was 
confirmed in the pancreas and lungs. Imaging studies using 111 In- and 68Ga- 
labeled compound 7 provided insufficient data to enable beta cell mass 
estimating but facilitated important discussion surrounding kidney uptake and 
retention of imaging probes. As a result, further imaging and biodistribution 
studies were conducted using compound 7 modified to avert kidney retention. 
Preliminary results demonstrated reduced kidney uptake and the imaging probe’s 
potential to provide insight into probe uptake in the pancreas.
4.2 GLP-1 Analogues with Superb Beta Cell Specificity 
in vitro
4.2.1 High Affinity for the GLP-1 R
In order to label our GLP-1 peptides with a PET or SPECT radioisotope, a
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator was 
conjugated to various residues within the structure of GLP-1. Positions 22Lys, 
26Lys, 34Lys or 37Lys (22Lys and 37Lys were substituted in place of 22Gly and 
37Gly, respectively) were chosen since none of these residues lie within the 
GLP-1 R recognition or binding sites (Adelhorst et al., 1994). The IC50S obtained 
by our novel GLP-1-based analogues were comparable to those of other GLP-1 
agonists in the literature; particularly compound 7 which had the strongest 
binding affinity. Naturally-occurring gallium-69/71-labeled exendin-3 was reported 
to have an IC50 of 5.7 nM (95% confidence interval 2.91 to 11.3 nM) using INS-1
64
cells (Brom et al., 2010). Naturally-occurring indium-113/115-labeled exendin-4 
displayed an IC50 of 2.1 ± 1.1 nM using beta tumor cells established from beta 
cell tumours of Rip1Tag2 mice (Wild et al., 2006). The discrepancy in IC50S may 
be due to the use of different cell lines for the binding assays, especially the beta 
tumour cell line which may have a higher expression of the GLP-1R than INS-1 
or CHO/GLP-1R cells.
It was hypothesized that the bulky DOTA chelator would hinder binding to the 
GLP-1 receptor by sterically hindering the essential binding sites of GLP-1. To 
avert this potential issue, a 2-[2-(2-aminoethyl)ethoxy]acetic acid (AEEA) spacer 
-  short chains of repeating polyethyleneglycol groups -  was inserted between 
the GLP-1 peptide chain and the DOTA chelator to assess if it could positively 
alter the binding affinity of the analogues. Based on the results, it was clear that 
the AEEA spacer had an effect on the binding of an analogue with DOTA placed 
mid-chain, by increasing its affinity 6-fold. The AEEA spacer did not, however, 
greatly alter the binding affinity of the analogue with DOTA placed at the C- 
terminus. To our knowledge, this was the first study to append DOTA to a mid­
chain residue of GLP-1; furthermore, one particular analogue with DOTA at 
22Lys, spaced by AEEA, demonstrated a strong affinity for the GLP-1 R. Thus, 
our results substantiate further exploration of imaging probes that carry DOTA 
mid-chain, in addition to exploiting the C-terminus for functional group attachment 
to, for example, alter its pharmacokinetics in vivo.
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4.2.2 Compounds 2, 7 and 8 are GLP-1R Agonists
Biological activity can be confirmed in analogues with a similar EC5o as GLP-1. 
One study reported an EC5o of 0.6 ± 0.2 nM for native GLP-1, a comparable 
value to our reported EC50 of 0.04 ± 0.02 nM (Irwin et al., 1997). Because of their 
comparable EC50 values, compounds 2, 7 and 8 were certainly GLP-1 R agonists. 
When GLP-1 R agonists are bound to the GLP-1 R in vivo, the ligand-receptor 
complex is internalized into the endosomal compartment, and the GLP-1 R is 
continuously recycled at the cell’s surface (Widmann et al., 1995). Thus, as 
imaging probes, compounds 2, 7 and 8 are internalized and will accumulate to 
facilitate accurate beta cell mass estimation.
4.2.3 Enhancing GLP-1 Stability
All analogues had a D-Ala conformation at 2Ala to resist enzymatic degradation 
by dipeptidyl peptidase-4 (DPP-IV) (Siegel et al., 1999). The D-Ala conformation 
has been shown to reduce the rate at which GLP-1 is metabolized from 1.59 to 
1.28 nmol/10 min * 5 pg membrane protein (Siegel et al., 1999). Native GLP-1 
(7-36) amide has been reported in the literature to have an in vitro half-life of 28.1 
± 1.2 min in porcine plasma (Deacon et al., 1998) and 20.4 ± 1.4 min in human 
plasma (Deacon, Johnsen, & Holst, 1995) which were similar to our reported half 
life of 15 min.
To confirm that this modification increased the half-life of a candidate imaging 
probe in vitro, compound 7 and native GLP-1 were tested for stability in rat 
serum. Compared with 111 In-labeled exendin-4, compound 7 displayed a similar
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decay pattern up until later time points. For example, at 4.5 hrs, analytic HPLC 
showed that 82.1% of 111ln-exendin-4 was still intact compared to compound 7 
showing 79.4% at the same time point interpolated based on the simulated decay 
curve in Figure 5 (Wild et al., 2006). Conversely, at 24 hrs, 73.7% of 111ln- 
exendin-4 was still intact compared to 27.0% of compound 7. This can be 
explained by the main difference between GLP-1 and exendin-4, particularly at 
the N-terminus: exendin-4 lacks the 2Ala that makes GLP-1 a suitable substrate 
for enzymatic cleavage by DPP-IV. Thus, exendin-4 is naturally resistant to 
enzymatic degradation in the plasma. It is necessary that an imaging probe 
preserve its stability at later time points when imaging is taking place several 
hours to days P.l. using long-lived isotopes such as indium-111. On that note, it 
is not necessary for a GLP-1 analogue to last over 24 hrs when using short-lived 
isotopes such as gallium-68 for in vivo imaging. Based on our study, the last 
imaging session occurred at 4 hrs P.l. of 68Ga-7, thus an imaging probe must 
have a half-life of at least 8 hrs to ensure a significant amount of the probe is not 
degraded during imaging. Therefore, compound 7’s modification renders it 
sufficiently stable for one imaging session lasting a few hours.
4.3 Targeting the GLP-1 R for SPECT and PET 
Imaging of the Beta Cell
4.3.1 Specific Uptake in the Pancreas
Biodistribution assays are commonly performed using mice or rats to examine 
the global uptake of GLP-1 R probes. In imaging beta cell mass, one must use 
caution when translating probe uptake values in mice to humans: mouse and rat
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islets express a higher proportion of beta cells to any other endocrine cell (77 %) 
in the islet in comparison to human islets (55 %) (Cabrera et al., 2006; de Franga 
Carvalho, Martins, da Cunha, Boschero, & Collares-Buzato, 2006). Nevertheless, 
the higher beta cell ratio implies higher GLP-1R expression, thereby providing a 
sizeable biomarker concentration for imaging the relatively small beta cells (1.30 
± 0.2 mg at 13 wks) in vivo in mice (Sreenan et al., 1999). Using 111 ln-2 as our 
first imaging probe, it was decided that 4 and 24 hrs were optimal time points to 
conduct biodistribution assays using C57BL/6 mice for two reasons. First, the 
long half-lives of both 111 In (U12 = 2.82 days) and our modified peptide allow for 
imaging sessions to take place several hours P.l. Second, three previous studies 
using 111ln-labeled GLP-1R imaging probes performed biodistribution assays at 4 
and 24 hrs, mainly to observe probe uptake in the pancreas as well as to 
understand probe clearance at these later time points (Gotthardt et al., 2006; 
Hassan et al., 1999; Wild et al., 2006). Uptake of 111 ln-2 in the pancreas 
remained constant at 4 % ID/g tissue at 4 and 24 hrs. Our uptake values at the 
4h time point lie within the range of those reported for other SPECT/gamma 
probes used for GLP-1R targeting such as: 111ln-exendin-4 (using Rip1Tag2 
mice), 21.1 % ID/g tissue; 131l-GLP-1(7-36)amide (using male Sprague-Dawley 
rats), 0.4 % ID/g tissue (at 5 hrs); and 111ln-exendin-3 (using female BALB/c nude 
mice bearing subcutaneous INS-1 tumours), 17.5 % ID/g tissue (Brom et al., 
2010; Hassan et al., 1999; Wild et al., 2006). At 24 hrs, uptake in the pancreas 
was 4.0 % fo r 111 ln-2 compared to 20.1 % ID/g tissue for 111ln-exendin-4 and 0.4 
% ID/g tissue (at 20 hrs ) fo r131 l-GLP-1 (7-36) amide (Hassan et al., 1999; Wild et
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al., 2006) Differences in probe uptake may be explained by several factors, 
including: the use of different mouse strains, mouse gender, differences in age, 
and the dose injected. The ratio of uptake in the pancreas to surrounding organs 
is a key determinant in selecting an appropriate imaging time. It was determined 
that 4 hrs was the best time for imaging the pancreas in vivo using pSPECT/CT 
since the pancreas to kidney uptake ratio was highest. The signal emitted from 
the kidney region was surprising since, based on the biodistribution assay, 
uptake in the pancreas was 8-times higher in the pancreas than the kidney (4 vs. 
0.5 % ID/g tissue).
Blocking studies, conducted at 4 hrs using excess exendin (9-39), confirmed that 
the uptake was GLP-1R-mediated. In addition to the pancreas, specific uptake 
was confirmed in other organs known to express the GLP-1 receptor, such as the 
heart and lungs (Wei & Mojsov, 1995). More surprisingly, the kidney and gut 
(intestines) displayed significant displacement and, therefore, uptake was GLP- 
1R-mediated. This finding reflects early studies confirming GLP-1 R expression in 
the bowels of rats, and in the kidneys and intestines of human tissues (Dunphy, 
Taylor, & Fuller, 1998; Korner et al., 2007). Blocking studies using 111ln-exendin- 
4 and 111ln-exendin-3 similarly demonstrated significant displacement in the 
lungs and pancreata of both mice and rats (Brom et al., 2010; Gotthardt et al., 
2006). Intestinal displacement of 111ln-exendin-4 by excess unlabeled peptide 
was non-significant due to the large standard deviation (Gotthardt et al., 2006). 
One interesting observation from the present study involves probe uptake in the 
kidneys following co-injection of excess cold peptide: although we observed
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significant displacement, other studies using 111 In-labeled GLP-1R targeting 
probes, more often than not, observed an increase in probe uptake in the 
kidneys. This finding provides evidence that uptake of 111ln-exendin-4 in the 
kidneys is predominantly due to peptide clearance whereas uptake of 111ln-GLP- 
1 in the pancreas is GLP-1R-mediated. Similarly, these studies have not found 
significant probe uptake in the heart. On this note, our probe may be used to 
provide insight toward the function of the GLP-1 in the heart using GLP-1-based 
imaging probes.
4.3.2 Imaging the Beta Cell using Radiolabeled Compound 2
While probe uptake was evident in the pancreas according to the results of the 
biodistribution, this finding was not reflected in pSPECT images. Only ex vivo 
gamma camera imaging allowed for visualization of probe uptake in the 
pancreas. The high signal intensity emitted from the liver was not surprising since 
it has been shown that GLP-1 is partly metabolized in the liver of pigs (Simonsen, 
Holst, & Deacon, 2006). The signal in the heart, however, was interesting since it 
is controversial as to whether the heart expresses the GLP-1 R (Gotthardt et al., 
2006; Wei & Mojsov, 1995).
Employing DOTA as a chelator enables the stable coordination of both 111 In and 
68Ga to generate a SPECT or PET imaging probe, respectively. Previous studies 
using 111 In-labeled exendin-3 and exendin-4 have coordinated 68Ga with the 
DOTA chelator to facilitate GLP-1 R imaging using PET (Brom et al., 2010; Wild 
et al., 2010). Small animal PET imaging offers similar sensitivity and spatial
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resolution as pSPECT, thus PET was employed to image the beta cells in vivo 
using 68Ga-7.
Dynamic pPET imaging provided little information regarding probe uptake in the 
beta cells; however, this finding is consistent with results of a PET imaging study 
using 68Ga-exendin-3 to localize INS-1 tumours with high GLP-1R expression, 
injected into the hind-limb of BALB/c mice. PET images of mice 1 hr P.I. of 68Ga- 
exendin-3 revealed high signal intensity from the kidneys and hind-limb tumour, 
with no clear delineation of the pancreas (Brom et al., 2010). Several successful 
attempts have been made at imaging insulinomas over-expressing the GLP-1R 
in mice and humans using 68Ga-exendin-3 and 111ln- and 68Ga-labeled exendin-4 
(Brom et al., 2010; Christ et al., 2009; Wild et al., 2010). These probes are 
evidently accumulating in the kidney to such an extent that any signal from the 
pancreas is obscured. Consequently, these probes may be most useful in 
imaging insulinomas and not intact beta cell mass.
Based on current literature, 111ln-exendin-4 was the only GLP-1R probe that 
began to explore imaging of healthy beta cells in vivo; however, no probe has 
been able to facilitate quantitative estimation of beta cell mass (Gotthardt et al., 
2006).
4.3.3 Exploring Tissue-Specific Probe Uptake
We used two strains of mice to examine the uptake of 68Ga-7; CD1 and C57BL/6. 
CD1 mice are outbred have been used to study the cytoarchitecture of the beta 
cells (Tornehave et al., 2008). C57BL/6 mice are inbred and serve as a
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background for the commonly used Rip1Tag2 mouse that spontaneously 
develops insulinomas, as well as studies investigating diabetes progression 
following treatment with streptozotocin (Li et al., 2005; Wicki et at., 2007). 
Biodistribution assays were conducted at 3-5 min P.l. based on the results of 
pPET imaging, and also at 4 hrs: the ideal time point used for 111 ln-2. Probe 
uptake values in all tissues of CD1 mice, including the pancreas, were extremely 
variable. One explanation for the higher probe uptake is that CD1 mice have 
been shown to express the GLP-1R in the large pancreatic ducts; further 
exploration of this theory is discussed below (Tornehave et al., 2008). The large 
variance in probe uptake can be attributed to the fact that CD1 mice are an 
outbred strain. A previous study aimed at investigating growth of Candida 
albicans using inbred and outbred mouse strains resolved to discontinue use of 
CD1 mice in further studies due to irreproducible results (Diez-Orejas et al., 
1997). Due to the high variance in probe uptake with and without co-injection of 
exendin (9-39), statistically significant displacement could not be confirmed in 
any organs known to express the GLP-1R. As a result, biodistribution assays 
were conducted at the same time points using C57BL/6 mice in hopes that 
selection of an inbred strain would aid in reducing the variability in probe uptake. 
As predicted, probe uptake in the pancreas at 3 min and 4 hrs was less variable 
between mice; however, the mean uptake values were lower than those in CD1 
mice. Using C57BL/6 mice allowed for more accurate statistical calculations of 
specific binding since standard error of the means were smaller. Both the 
pancreas and the lungs displayed significant displacement and uptake, therefore,
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was GLP-1R mediated. These results were consistent with the study 
investigating uptake of 68Ga-exendin-3 in BALB/c mice bearing INS-1 tumours in 
the hind-limb 1 hr P.l. (Brom et al., 2010; Gotthardt et al., 2006; Wicki et al., 
2007; Wild et al., 2010). Furthermore, GLP-1 R-mediated uptake -  confirmed by 
displacement following co-injection of excess unlabeled exendin-3 -  was 
confirmed in the pancreas and in the hind-limb tumours. In addition to the high 
probe uptake in the kidneys, the main problem preventing further examination of 
beta cell mass in vivo using PET was the relatively high -  although non-specific -  
uptake in organs surrounding the pancreas including the liver, spleen and 
intestines (gut).
4.4 Exploring Differences in Probe Uptake in Two 
Strains of Mice
Ours is the first study, known to us, to show differences in GLP-1 R probe uptake 
between strains of mice. Based on the results from the biodistribution assay, it 
was evident that we needed to explore the reason for the difference in uptake of 
68Ga-7. Therefore, it was necessary to examine these differences at the tissue 
level in CD1 and C57BL/6 mice. Particularly, we wanted to investigate the 
previously reported observation that GLP-1 Rs are expressed in the large 
pancreatic ducts of CD1 mice thereby accounting for the large variance in probe 
uptake between mice (Tornehave et al., 2008). To address this question, I 
carried out fluorescence immunohistochemistry on pancreatic sections from both 
strains of mice for insulin and the GLP-1 R in an attempt to co-localize beta cells 
with the GLP-1 R and, furthermore, investigate GLP-1 R expression in other areas
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of the pancreas such as the exocrine acinar cells and ductal cells. However, 
immunostalning was unsuccessful because the GLP-1R antibody did not target 
GLP-1R tissues and further analysis of GLP-1R colocalization with cytokeratin, 
amylase and insulin could not be accomplished. Evidently, further analysis is 
warranted to explore strain differences in probe uptake.
4.5 Structural Modifications to Reduce Renal Probe 
Accumulation
According to Vegt et al., 2010, the kidneys are the main excretory pathway for 
hydrophilic radiolabeled peptides which get reabsorbed in the proximal tubular 
cells, thereby contributing to peptide retention. When radiolabeled peptides 
weigh more than 12 kDa, such as GLP-1 and exendin-4, they cannot be actively 
filtered through the glomerular membrane. Thus, they are reabsorbed in the 
proximal tubules via receptor-mediated endocytosis and become trapped in the 
lysosomes where they are referred to as ‘residualizing radiolabels’ (Vegt et al., 
2010). Several strategies were suggested to reduce renal uptake, including: 
structurally modifying radiolabeled compounds; using different radiolabels, linkers 
or chelators; and competitively inhibiting proximal tubular reabsorption (Vegt et 
al., 2010). One group even went as far as removing the kidneys altogether to 
obtain a better PET signal from Rip1Tag2 mice injected with 68Ga-exendin-4 
(Wild et al., 2010). In addition, this group performed a renal reduction study using 
poly-glutamic acid (PGA) and Gelofusine, which, when co-injected with 68Ga- 
exendin-4, significantly reduced kidney uptake. In attempts to avoid invasive 
techniques such as nephrectomy or co-injecting chemicals to reduce renal
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peptide retention, we synthesized another GLP-1 analogue by modifying the 
charges of compound 7 through the addition of acyl groups, thereby increasing 
hydrophobicity and reducing the charge on the peptide. This type of modification 
was predicted to reduce renal retention (Vegt et al., 2010). Our preliminary 
biodistribution data using acylated 68Ga-7 suggested reduced kidney retention at 
4 hrs compared to 68Ga-7. Preliminary pPET imaging demonstrated a dramatic 
reduction in kidney retention throughout a 1 hr dynamic scan and 4 hrs P.l. 
However, despite the reduction in kidney uptake, we were still unable to visualize 
the pancreas. The lack of signal in the pancreas was not due to altered binding 
affinity of acylated 68Ga-7, as the IC50 was similar to that of 68Ga-7. Several 
groups have successfully reduced renal retention and increased the target-to- 
kidney ratio through the modification of the structure (adding or removing 
functional groups), adding/removing linker and chelators of radiolabeled 
peptides, or co-injecting competitive inhibiting compounds (Vegt et al., 2010). 
One such group made efforts to reduce kidney uptake of 68Ga-exendin-4 in 
Rip1Tag2 mice by co-injecting L-poly-glutamic acid and Gelofusine, a gelatin- 
based plasma expander (Wild et al., 2010). Although kidney uptake was reduced 
by 78%, this technique was still insufficient to visualize insulinomas. Their PET 
images looked similar to the ones we obtained during PET imaging with acylated 
68Ga-7; particularly, the high signal intensity in the kidneys that obscures signal 
from the pancreas. Our study is the first, known to us, that has modified the 
peptide structure of a GLP-1-based analogue to reduce kidney retention.
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In summary, a number of GLP-1R probes have been developed in hopes of 
eventually quantifying beta cell mass in vivo using nuclear imaging techniques. 
Many of these probes have been extensively characterized but few have 
successfully imaged the pancreas. Although preliminary imaging studies using 
exendin-4 seemed promising, the research team has resolved to venture down 
the path of imaging insulinomas, and not normal beta cell mass, in vivo. Thus, it 
appears that imaging endogenous beta cells using GLP-1R probes has proven 
difficult for all research groups attempting to achieve this goal. Although the use 
of rodents for imaging studies has advantages (including cost effectiveness and 
transferability of findings), their pancreata, small and in close proximity to the 
kidneys, are extremely difficult to image in vivo. This thesis project provided a 
comprehensive analysis of several novel GLP-1 -based radioprobes, both in vitro 
and in vivo. Our imaging and biodistribution results were consistent with the 
current literature and, with slight modifications, compound 7 has proven to have 
the highest potential to image beta cells in vivo.
4.6 Future Directions
Based on the unique results between uptake values of 68Ga-7 in CD1 and 
C57BI/6 mice, it is evident that further examination is warranted to explore these 
differences. One study investigating the suitability of the GLP-1 R as a biomarker 
for neuroendocrine tumour imaging used autoradiography to detect 125I-GLP-1(7- 
36)amide binding in several tissues (Korner et al., 2007). Similarly, 
autoradiography can be employed to detect 125l-GLP-1(7-36)amide binding in
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pancreatic tissues of CD1 and C57BL/6 mice; particularly, if GLP-1R expression 
in ductal cells of CD1 mice can explain for the high variation in probe uptake.
Preliminary imaging and biodistribution results using acylated compound 7 
revealed a significant reduction of renal retention at early time points. 
Biodistribution assays will be completed by increasing the sample sizes and by 
co-injecting excess exendin (9-39) to examine GLP-1-mediated uptake. Further 
modifications to compound 7 may be warranted to optimize its uptake in the 
pancreas and significantly reduce renal retention.
Although much improvement in imaging technology and targeted-peptide 
development has brought us one step closer to imaging the beta cells, no tried- 
and-tested method has been implemented clinically. Obviously, there is still much 
improvement to be made to actually image euglycemic and dysfunctional beta 
cell mass, in vivo. One limitation of using nuclear imaging techniques (PET and 
SPECT) to facilitate beta cell imaging is their limited spatial resolution. Several 
studies employing SPECT and PET to image beta cells using target probes have 
also combined MRI or CT to more accurately localize the tissue from which 
signal was emitted (Brom et al., 2010; Gotthardt et al., 2006; Wicki et al., 2007; 
Wild et al., 2010). Two of these studies were able to localize the SPECT signals 
to the pancreas based on fused images with MRI or CT (Gotthardt et al., 2006; 
Wild et al., 2010); however, MRI seemed to offer the best spatial resolution. 
Based on our results, it was evident that fusing the SPECT and PET images with
77
MRI will help to examine if any of the signal is emitted from the pancreas which is 
only a few mm away from the kidneys.
The GLP-1R has been established as a suitable biomarker for beta cell imaging 
and is reflected in the number of probes developed to target it. All of these GLP- 
1 R-targeted probes are now focused on imaging insulinomas that have a 6-fold 
higher GLP-1 R density than normal beta cells. The over-expressed GLP-1 R 
serves as a suitable target for insulinoma imaging; however, normal expression 
of the GLP-1 R may not be a large enough target for in vivo imaging. The 
identification of an alternate biomarker that is specific to the beta cells in the 
pancreas and expressed in high enough density to allow quantitative imaging is 
warranted. A cell membrane protein, vesicular monoamine transporter type 2 
(VMAT2), has been identified as an islet-specific biomarker and ideal for beta cell 
imaging using radiolabeled dihydrotetrabenazine (DTBZ) (Maffei et al., 2004). 
Although a moderate correlation (R2 = 0.50) existed between beta cell function 
and 11C-DTBZ uptake measurements in the pancreas of diabetic and control 
patients imaged with PET, it was suggested that VMAT2 may be expressed in 
non-endocrine tissues of the pancreas and thus, 11C-DTBZ uptake may 
overestimate beta cell mass (Goland et al., 2009). Still, further investigation into 
biomarkers specific to the beta cell is required; a biomarker that is consistently 
expressed in beta cells during diabetes progression is ideal to provide a sufficient 
SPECT or PET signal to be quantified.
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